Source: Breathe, 17 (4) 210144; 10.1183/20734735.0144-2021



Rating:

Share or cite this content

Citations should be made in the following way:
Joanne E. Kavanagh, Andrew P. Hearn, David J. Jackson. A pragmatic guide to choosing biologic therapies in severe asthma. Breathe, 17 (4) 210144; 10.1183/20734735.0144-2021

Member's Comments

No comment yet.

Related content which might interest you: Recommended new therapies for severe asthma and the future Source: International Congress 2014 – PG05 Severe asthma – highlights from the ERS/ATS workshop Year: 2014 Recommendations of new therapies for severe asthma and the future Source: Annual Congress 2013 –ERS/ATS Task Force report on severe asthma Year: 2013 Who should receive which biologic and why? Current and future approaches in severe asthma patients Source: Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what? Year: 2021 A digital therapy for proactively managing exacerbations and delivering therapeutic benefit to patients with moderate to severe asthma Source: International Congress 2019 – Clinical approach to asthma management Year: 2019 A new GINA resource in 2018: a practical guide for assessing and managing difficult-to-treat and severe asthma Source: International Congress 2018 – GINA 2018 and beyond: shaping the future of asthma management Year: 2018 COVID-19 conundrum: clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness Source: Eur Respir J, 56 (2) 2002135; 10.1183/13993003.02135-2020 Year: 2020 Emerging biologic approaches for the treatment of difficult to control asthma Source: International Congress 2017 – Pathophysiology and emerging therapies for severe asthma Year: 2017 Can we use a biomarker to guide antibiotic treatment in severe COPD exacerbations? Source: Breathe, 15 (4) 353; 10.1183/20734735.0257-2019 Year: 2019 New and future developments of therapy for asthma in children Source: Eur Respir Mon 2012; 56: 224-234 Year: 2012 Identifying patients with severe asthma that will be benefit from biological therapy Source: Virtual Congress 2020 – Rethinking asthma Year: 2020 Do we need new therapies for noneosinophilic asthma? Source: Annual Congress 2004 - Noneosinophilic asthma Year: 2004 Revising our approach to conducting therapeutic clinical research in COPD Source: Eur Respir J, 51 (2) 1702712; 10.1183/13993003.02712-2017 Year: 2018 Measuring airway hyperresponsiveness: does it add to routine measures of clinical efficacy in guiding asthma therapy? Source: Eur Respir J 2006; 28: Suppl. 50, 319s Year: 2006 Efficient and practical management for checking inhalation technique and discussing medication adherence before treatment step-up in uncontrolled asthma Source: International Congress 2018 – Asthma: clinical screening tools Year: 2018 From guidelines to personalized treatment of children with asthma Source: Virtual Congress 2020 – Which paediatric asthma guidelines are the most appropriate for children and adolescents? Year: 2020 Pharmacological strategies for self-management of asthma exacerbations Source: Eur Respir J 2006; 28: 182-199 Year: 2006 Use of relievers in patients with severe asthma on biologic therapy –a multidisciplinary approach Source: Virtual Congress 2020 – Challenges and updates in nursing care around the world Year: 2020 Comparative efficacy of the therapy strategies for the asthma control maintenance in real clinical practice Source: Annual Congress 2011 - Asthma: control and treatment Year: 2011 Is poor asthma self-management due to failure to recognise symptoms or failure to act? Novel insights from mining large-scale clinical observational study Source: International Congress 2019 – M-health/e-health II Year: 2019